Targeted Cancer Therapeutic

helping patients who have limited or no cancer treatment options because of EGFR-TKI resistant tumors

Epidermal Growth Factor Receptor (EGFR) drives cancer progression in a large number of solid tumors in patients, and EGFR inhibitors are the current standard of care. However, while patients may respond to treatment initially, nearly all will develop resistance within a year.

Researchers from the University of Michigan have developed Disruptin, a novel peptide, and two small molecules that are effective in inhibiting EGFR in tumors without manifesting toxicities or affecting the EGFR in adjacent host tissues.

Significant Need

The peptide drug provides a treatment option for EGFR-drive TKI resistant patients who currently don’t have any other therapeutic alternatives.

Competitive Advantage

Already developed and tested, Disruptin and the two small molecules do not affect the EGFR in adjacent host tissue and do not manifest the toxicities seen with other agents.

Commercialization Path

  • Intellectual Property – One patent for Disruptin published, one patent filed, and will soon disclose a third
  • Regulatory Pathway – Begin discussions with regulatory consultants regarding the quickest path to an Investigational New Drug (IND) approval
  • Engage Investors – A number of interested investors
  • Product Launch – Disruptin


  • Conduct in-vivo studies to assess pharmacodynamics (PD) of Disruptin in TKI resistant tumor model
  • Conduct in-vivo tests to assess pharmacokinetics (PK) of Disruptin in C57 mice
  • Establish correlation between dose and duration of treatment (schedule) with PK in TKI xenograft mouse model
  • Determine the maximum tolerated dose
  • Compare efficacy of Disruptin with standard of care to determine therapeutic index in TKI resistant EGFR dependent tumor models

May 2, 2017